Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

被引：3
|
作者：
Hellmann, M. D. [1 ]
Rizvi, N. [1 ]
Gettinger, S. N. [2 ]
Goldman, J. [3 ]
Chow, L. Q. [4 ]
Juergens, R. [5 ]
Borghaei, H. [6 ]
Brahmer, J. [7 ]
Shen, Y. [8 ]
Harbison, C. T. [9 ]
Nathan, F. [10 ]
Ready, N. E. [11 ]
Antonia, S. J. [12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] Yale Comprehens Canc Ctr, Med Oncol, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Hematol Oncol, Los Angeles, CA 90024 USA
[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[5] Juravinski Canc Ctr, Dept Oncol, Hamilton, ON, Canada
[6] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Oncol, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Immunosci Metab Dis & Fibrosis, Princeton, NJ USA
[10] Bristol Myers Squibb Co, Clin Res, Princeton, NJ USA
[11] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[12] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Dept, Tampa, FL 33612 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31738-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3097
引用
收藏
页码：S632 / S633
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer
    Peravali, Monica
    Ahn, Jaeil
    Chen, Kevin
    Rao, Suman
    Veytsman, Irina
    Liu, Stephen V.
    Kim, Chul
    ONCOLOGIST, 2021, 26 (08): : 694 - 700
  • [32] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Nivolumab (NIVO) plus ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Thomas, M.
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Bernabe Caro, R.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 141
  • [34] Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
    Hellmann, Matthew D.
    Ciuleanu, Tudor Eliade
    Pluzanski, Adam
    Lee, Jong Seok
    Otterson, Gregory
    Audigier-Valette, Clarisse
    Minenza, Elisa
    Linardou, Helena
    Burgers, Sjaak
    Salman, Pamela
    Borghaei, Hossein
    Ramalingam, Suresh S.
    Brahmer, Julie
    Reck, Martin
    O'Byrne, Kenneth J.
    Geese, William J.
    Green, George
    Chang, Han
    Szustakowski, Joseph D.
    Bhagavatheeswaran, Prabhu
    Healey, Diane
    Fu, Yali
    Nathan, Faith
    Paz-Ares, Luis
    CANCER RESEARCH, 2018, 78 (13)
  • [35] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [36] Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Ota, T.
    Kirita, K.
    Udagawa, H.
    Umemura, S.
    Matsumoto, S.
    Yoh, K.
    Niho, S.
    Goto, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
    Reinmuth, N.
    Reck, M.
    Ciuleanu, T. -E
    Cobo, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E.
    Bennouna, J.
    Felip, E.
    Juan-Vidal, O.
    Alexandru, A.
    Sakai, H.
    Scherpereel, A.
    Lu, S.
    Paz-Ares, L.
    Carbone, D. P.
    Memaj, A.
    Marimuthu, S.
    Tran, P.
    John, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 54
  • [38] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [39] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [40] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
    Reck, Martin
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345